Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites

Chemical Research in Toxicology

Volumn 19, Issue 7, 2006, Pages 914-920

  Avent, Kathryn M ^a,b   DeVoss, J J ^a   Gillam, Elizabeth M J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Queensland Ctr Schizophrenia Res   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 1 (4 FLUOROPHENYL) 4 HYDROXYBUTYL 1,2,3,6 TETRAHYDROPYRIDINE; 4 (4 CHLOROPHENYL) 1 (4 FLUOROPHENYL) 4 HYDROXYBUTYLPYRIDINIUM; 4 (4 CHLOROPHENYL) 1 (4 FLUOROPHENYL) 4 OXYBUTYL 1,2,3,6 TETRAHYDROPYRIDINE; 4 (4 CHLOROPHENYL) 1 (4 FLUOROPHENYL) 4 OXYBUTYLPYRIDINIUM; CATALASE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DRUG METABOLITE; GLUTATHIONE; HALOPERIDOL; PYRIDINIUM DERIVATIVE; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BACTERIAL MEMBRANE; CATALYST; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ASSAY; ESCHERICHIA COLI; HUMAN; HUMAN TISSUE; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; RAT;

BIOTRANSFORMATION; CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; HALOPERIDOL; HUMANS; MICROSOMES, LIVER; MODELS, BIOLOGICAL; MUTATION; OXIDATION-REDUCTION; PYRIDINIUM COMPOUNDS; RECOMBINANT PROTEINS;

ESCHERICHIA COLI;

EID: 33746255367     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx0600090     Document Type: Article

References (36)

1. Subramanyam, B., Rollema, H., Woolf, T., and Castagnoli, N., Jr. (1990) Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem. Biophys. Res. Commun. 166, 238-244.
2. Van der Schyf, C. J., Castagnoli, K., Usuki, E., Fouda, H. G., Rimoldi, J. M., and Castagnoli, N., Jr. (1994) Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice. Chem. Res. Toxicol. 7, 281-285.
3. Igarashi, K., and Castagnoli, N., Jr. (1992) Determination of the pyridinium metabolite derived from haloperidol in brain tissue, plasma and urine by high-performance liquid chromatography with fluorescence detection. J. Chromatogr., Biomed. Appl. 579, 277-283.
4. Subramanyam, B., Pond, S. M., Eyles, D. W., Whiteford, H. A., Fouda, H. G., and Castagnoli, N., Jr. (1991) Identification of potentially neurotoxic metabolite in the urine of schizophrenic patients treated with haloperidol. Biochem. Biophys. Res. Commun. 181, 573-578.
5. Eyles, D. W., McLennan, H. R., Jones, A., McGrath, J. J., Stedman, T. J., and Pond, S. M. (1994) Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. Clin. Pharmacol. Ther. 56, 512-520.
6. Avent, K. M. (2001) In Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol. Ph.D. Thesis, p 230, The University of Queensland, Brisbane, Australia.
7. Eyles, D. W., Avent, K. M., Stedman, T. J., and Pond, S. M. (1997) Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem. Life Sci. 60, 529-534.
8. Avent, K. M., Riker, R. R., Fraser, G. L., Van der Schyf, C. J., Castagnoli, N., Jr., and Pond, S. M. (1997) Metabolism of haloperidol to pyridinium species in patients receiving high doses intravenously: Is HPTP an intermediate? Life Sci. 61, 2383-2390.
9. Fang, J., and Gorrod, J. (1991) Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite. Toxicol. Lett. 59, 117-123.
10. Fang, J., and Gorrod, J. (1992) Metabolism of haloperidol by mouse hepatic microsomal preparations. Med. Sci. Res. 20, 175-177.
11. Gorrod, J., and Fang, J. (1993) On the metabolism of haloperidol. Xenobiotica 23, 495-508.
12. Fang, J., and Gorrod, J. (1993) High-performance liquid chromatographic method for the detection and quantitation of haloperidol and seven of its metabolites in microsomal preparations. J. Chromatogr. 614, 267-273.
13. Igarashi, K., Kasuya, F., Fukui, M., Usuki, E., and Castagnoli, N., Jr. (1995) Studies on the metabolsim of haloperidol (HP): The role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP. Life Sci. 57, 2439-2466.
14. Usuki, E., Pearce, R., Parkinson, A., and Castagnoli, N., Jr. (1996) Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes. Chem. Res. Toxicol. 9, 800-806.
15. Eyles, D. W., McGrath, J. J., and Pond, S. M. (1996) Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology 125, 214-219.
16. Fang, J., Baker, G. B., Silverstone, P. H., and Coutts, R. T. (1997) Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell. Mol. Neurobiol. 17, 227-233.
17. Kalgutkar, A. S., Taylor, T. J., Venkatarakrishnan, K., and Isin, E. M. (2004) Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab. Dispos. 31, 243-249.
18. Parikh, A., Gillam, E. M. J., and Guengerich, F. P. (1997) Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat. Biotechnol. 15, 784-788.
19. Shimada, T., Wunsch, R. M., Hanna, I. H., Sutter, T. R., Guengerich, F. P., and Gillam, E. M. J. (1998) Recombinant human cytochrome P450 1B1 expression in Escherichia coli. Arch. Biochem. Biophys. 357, 111-120.
20. Gillam, E. M. J., Aguinaldo, A. M., Notley, L. M., Kim, D., Mundkowski, R. G., Volkov, A. A., Amold, F. H., Soucek, P., DeVoss, J. J., and Guengerich, F. P. (1999) Formation of indigo by recombinant mammalian cytochrome P450s. Biochem. Biophys. Res. Commun. 265, 467-472.
21. Gillam, E. M. J., Notley, L. M., Cai, H., DeVoss, J. J., and Guengerich, F. P. (2000) Oxidation of indole by cytochrome P450 enzymes. Biochemistry 39, 13817-13824.
22. Cuttle, L., Munns, A. J., Hogg, N. A., Scott, J. R., Hooper, W. D., Dickinson, R. G., and Gillam, E. M. J. (2000) Phenytoin metabolism by human cytochrome P450: Involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab. Dispos. 28, 945-950.
23. Gillam, E. M. J., Ueng, Y.-F., Wunsch, R. M., Shimada, T., Kamataki, T., and Guengerich, F. P. (1997) Expression of cytochrome P450 3A7 in Escherichia coli: Effects of 5′ modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase. Arch. Biochem. Biophys. 346, 81-90.
24. Nishihara, K., Kanemori, M., Kitagawa, M., Yanagi, H., and Yura, T. (1998) Chaperone coexpression plasmids: Differential and synergistic roles of DnaK-DnaJ-GrpE and GroEL-GroES in assisting folding of an allergen of Japanese Cedar pollen, Cryj2, in Escherichia coli. Appl. Environ. Microbiol. 64, 1694-1699.
25. Guengerich, F. P. (1994) Analysis and characterization of enzymes. In Principles and Methods of Toxicology 3rd ed. (Hayes, A. W., Ed.), pp 1259-1313, Raven Press, Ltd., New York.
26. Notley, L. M., de Wolf, C. J. F., Wunsch, R. M., Lancaster, R. G., and Gillam, E. M. J. (2002) Bioactivation of tamoxifen by recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol. 15, 614-622.
27. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378.
28. Hutzler, J. M., and Tracy, T. S. (2002) Atypical kinetic profiles in drug metabolism reactions. Drug Metab. Dispos. 30, 355-362.
29. Guengerich, F. P. (2005) Human cytochrome P450 enzymes. In Cytochrome P450 3rd ed. (Ortiz de Montellano, P. R., Ed.), Kluwer Academic/Plenum Press, New York.
30. Lai, C. S., Grover, T. A., and Peitte, L. H. (1979) Hydroxyl radical production in a purified NADPH-cytochrome c (P450) reductase system. Arch. Biochem. Biophys. 193, 373-378.
31. Winston, G. W., and Cederbaum, A. I. (1983) NADPH-dependent production of oxy radicals by purified components of the rat liver mixed function oxidase system. I. Oxidation of hydroxyl radical scavenging agents. J. Biol. Chem. 258, 1508-1513.
32. Baez, S., and Seqgura-Aguilar, J. (1995) Effect of superoxide dismutase and catalase during reduction of adrenochrome by DT-diaphorase and NADPH-cytochrome P450 reductase. Biochem. Mol. Med. 56, 37-44.
33. Castagnoli, N., Jr., Chiba, K., and Trevor, A. J. (1985) Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). Life Sci. 36, 225-230.
34. +, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J. Med. Chem. 28, 1432-1436.
35. Gessner, W., Brossi, A., Shen, R., and Abell, C. W. (1985) Further insight into the mode of action of the neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). FEBS Lett. 183, 345-348.
36. Subramanyam, B., Woolf, T., and Castagnoli, N., Jr. (1991) Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. Chem. Res. Toxicol. 4, 123-128.